Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway.


Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
18 06 2019
Historique:
entrez: 19 6 2019
pubmed: 19 6 2019
medline: 21 10 2020
Statut: epublish

Résumé

NK cell exhaustion (NCE) due to sustained proliferation results in impaired NK cell function with loss of cytokine production and lytic activity. Using murine models of chronic NK cell stimulation, we have identified a phenotypic signature of NCE characterized by up-regulation of the terminal differentiation marker KLRG1 and by down-regulation of eomesodermin and the activating receptor NKG2D. Chronic stimulation of mice lacking NKG2D resulted in minimized NCE compared to control mice, thus identifying NKG2D as a crucial mediator of NCE. NKG2D internalization and downregulations on NK cells has been previously observed in the presence of tumor cells with high expression of NKG2D ligands (NKG2DL) due to the activation of the DNA damage repair pathways. Interestingly, our study revealed that during NK cell activation there is an increase of MULT1, and NKG2DL, that correlates with an induction of DNA damage. Treatment with the ATM DNA damage repair pathway inhibitor KU55933 (KU) during activation reduced NCE by improving expression of activation markers and genes involved in cell survival, by sustaining NKG2D expression and by preserving cell functionality. Importantly, NK cells expanded ex vivo in the presence of KU displayed increased anti-tumor efficacy in both NKG2D-dependent and -independent mouse models. Collectively, these data demonstrate that NCE is caused by DNA damage and regulated, at least in part, by NKG2D. Further, the prevention of NCE is a promising strategy to improve NK cell-based immunotherapy.

Identifiants

pubmed: 31211693
pii: 127729
doi: 10.1172/jci.insight.127729
pmc: PMC6675585
doi:
pii:

Substances chimiques

2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one 0
Histocompatibility Antigens Class I 0
Klrk1 protein, mouse 0
Membrane Proteins 0
Morpholines 0
NK Cell Lectin-Like Receptor Subfamily K 0
Pyrones 0
UL16 binding protein 1, mouse 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCI NIH HHS
ID : P01 CA049605
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA124435
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA125276
Pays : United States

Références

J Immunol. 2002 Oct 15;169(8):4079-83
pubmed: 12370332
Immunity. 2004 Jun;20(6):757-67
pubmed: 15189740
J Immunol. 2004 Jul 1;173(1):259-66
pubmed: 15210783
J Exp Med. 2005 Jan 17;201(2):211-20
pubmed: 15642742
Blood. 2005 Sep 1;106(5):1711-7
pubmed: 15886320
Nature. 2005 Aug 25;436(7054):1186-90
pubmed: 15995699
Nat Immunol. 2005 Sep;6(9):938-45
pubmed: 16086018
Nat Immunol. 2005 Sep;6(9):928-37
pubmed: 16116470
Proc Natl Acad Sci U S A. 2006 May 2;103(18):7012-7
pubmed: 16627620
J Immunol. 2007 Apr 15;178(8):4764-70
pubmed: 17404256
Blood. 2007 Jul 15;110(2):606-15
pubmed: 17405908
Immunity. 2008 Apr;28(4):571-80
pubmed: 18394936
Biol Blood Marrow Transplant. 2008 Oct;14(10):1088-1099
pubmed: 18804038
J Exp Med. 2009 Feb 16;206(2):287-98
pubmed: 19171762
J Immunol. 2009 May 15;182(10):6600-9
pubmed: 19414815
Immunity. 2009 Aug 21;31(2):270-82
pubmed: 19631564
Int J Cancer. 2011 Jul 15;129(2):387-96
pubmed: 20853320
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21647-52
pubmed: 21098276
PLoS Pathog. 2011 Jan 13;7(1):e1001254
pubmed: 21249177
Blood. 2011 May 5;117(18):4778-86
pubmed: 21406724
Blood. 2011 Jun 30;117(26):7032-41
pubmed: 21498673
Blood. 2011 Jun 30;117(26):7007-13
pubmed: 21518931
J Clin Invest. 2011 Sep;121(9):3609-22
pubmed: 21841316
PLoS Pathog. 2011 Sep;7(9):e1002265
pubmed: 21966273
Nature. 2011 Nov 20;481(7381):394-8
pubmed: 22101430
Blood. 2012 Feb 9;119(6):1590-8
pubmed: 22184406
Immunity. 2012 Jan 27;36(1):132-41
pubmed: 22244846
Blood. 2012 Jun 14;119(24):5758-68
pubmed: 22544698
Viral Immunol. 2012 Aug;25(4):329-32
pubmed: 22742708
Hepatology. 2013 Jan;57(1):277-88
pubmed: 22806577
Cancer Cell. 2012 Nov 13;22(5):645-55
pubmed: 23153537
Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):E3578-87
pubmed: 23169621
Curr Opin Immunol. 2013 Apr;25(2):214-21
pubmed: 23298609
Int J Hematol. 2013 May;97(5):581-98
pubmed: 23585244
Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7401-6
pubmed: 23589894
Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9421-6
pubmed: 23690625
J Immunol. 2013 Jul 15;191(2):688-98
pubmed: 23752612
J Virol. 2013 Nov;87(21):11626-36
pubmed: 23966413
Clin Immunol. 2013 Dec;149(3):432-9
pubmed: 24211717
Blood. 2014 May 1;123(18):2882-92
pubmed: 24591203
J Immunol. 2014 May 15;192(10):4487-91
pubmed: 24740507
J Virol Methods. 2014 Sep 1;205:53-6
pubmed: 24747009
J Immunol. 2014 Aug 15;193(4):1709-16
pubmed: 25000978
PLoS One. 2014 Oct 06;9(10):e108326
pubmed: 25286418
Aging Cell. 2015 Apr;14(2):191-9
pubmed: 25677698
Science. 2015 Apr 3;348(6230):136-9
pubmed: 25745066
Oncoimmunology. 2015 Jan 7;3(12):e946365
pubmed: 25964857
J Immunol. 2015 Nov 15;195(10):4712-20
pubmed: 26438526
J Exp Med. 2016 Feb 8;213(2):225-33
pubmed: 26755706
Nat Immunol. 2016 Jul;17(7):816-24
pubmed: 27213690
Front Immunol. 2016 Jun 20;7:241
pubmed: 27379101
Oncotarget. 2016 Oct 18;7(42):68513-68526
pubmed: 27655680
Oncotarget. 2016 Nov 8;7(45):72961-72977
pubmed: 27662664
Blood. 2016 Dec 15;128(24):2846-2858
pubmed: 27760760
Oncoimmunology. 2016 Dec 7;6(2):e1261242
pubmed: 28344869
Front Immunol. 2017 Apr 25;8:465
pubmed: 28487696
Nat Commun. 2017 Jun 06;8:15776
pubmed: 28585539
Immunohorizons. 2017 May 1;1(3):10-19
pubmed: 28815225
Elife. 2017 Dec 12;6:
pubmed: 29231815
JCI Insight. 2018 Feb 8;3(3):null
pubmed: 29415897
Nat Immunol. 2018 Oct;19(10):1083-1092
pubmed: 30224819

Auteurs

Maite Alvarez (M)

Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, California, USA.

Federico Simonetta (F)

Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, California, USA.

Jeanette Baker (J)

Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, California, USA.

Antonio Pierini (A)

Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, California, USA.

Arielle S Wenokur (AS)

Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, California, USA.

Alyssa R Morrison (AR)

Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, California, USA.

William J Murphy (WJ)

Department of Dermatology and Internal Medicine, University of California, Davis, Sacramento, California, USA.

Robert S Negrin (RS)

Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH